Physiological and histological effect of Captopril on kidney and the protective role of Brassica nigra seed extract in male rats
Article Sidebar
Main Article Content
Abstract
The experiment was designed to determine the protective role of Brassica nigra seed extract on Kidney function and tissue against the negative effects induced by the drug Captopril (CPT25 and CPT50).
In this experiment, 30 animals (Rats male) were used. Kidney efficiency was measured by measuring The level of urea and creatinine and level of Glutathion (GSH), Malondialdehyde (MDA) and Superoxide dismutase (SOD) in kidney tissue, as well as studying the histological effects of the drug Captopril (CPT25 and CPT50). against ،Kidney tissue and the protective role of Brassica nigra seed extract . The results showed that the treatment of animals with drug Captopril (CPT25 and CPT50) at a dose of 1.9 and 3.8 mg / kg bw for 30 days led to a significant increase in The level of urea, creatinine, (MDA), (SOD) and decrease in The level of (GSH).
The treatment of animals with drug Captopril (CPT25 and CPT50) has shown Effected on kidney tissues cases the infiltration and inflammatory of inflammatory cells between the urinary tubules, the presence of hemorrhage within the kidney tissue and the renal glomeruli, and cellular degeneration of some cells of the urinary tubules. Brassica nigra seed extract improves most of the negative effects caused by drug Captopril (CPT25 and CPT50).
The aim of this study is to investigate the negative effects of captopril on kidney tissues, and to identify the protective role of Brassica nigra seed extract against the negative effected of captopril on some biochemical and histological parameters.
The conclusion from this study is that the drug Captopril showed an effected on the kidneys of the experimental animals, represented by the emergence of tissue lesions in the organ tissues, and through the results of the results, the protective effected of Brassica nigra seed extract against the effects of captopril was identified.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Berves, G.; Gregory, Y. and Brien, E. (2001). Hypertension: Blood pressure measurement. British Med. J. 322 (21):981-985.
[2] Giles, T.D.; Berk, B.C.; Black, H.R.; Cohn, J.N.; Kosti,s J.B., Izzo, J.L., and Weber, M.A. (2005). Expanding the Definition and Classification of Hypertension. Journal of Clinical Hypertension, 7(9): 505-512.
[3] Al-jumaily, H. F., Sarhan, Y. T., & Alhayani, A. K. (2017). Risk Factors of Pregnancy Induced Hypertension in Falluja City. Al-Anbar Medical Journal, 14(1), 58-63.
[4] Mousa, Z. A., Al-Shawi, N. N., & Omar, A. A. (2015). Study the Influence of Captopril on Bone Metabolism in Elderly Hypertensive Women. Iraqi Journal of Pharmaceutical Sciences, 24(1), 11-17.
[5] Al-Youzbaki, W.B., & YT Al-Taee, Y. (2013). Serum uric acid level and renal function tests in hypertensive patients treated by captopril. Iraqi Journal of Pharmacy, 13(2), 1-10.
[6] Lindberg, H., Nielsen, D., Jensen, B. V., Eriksen, J., & Skovsgaard, T. (2004). Angiotensin converting enzyme inhibitors for cancer treatment?. Acta oncologica (Stockholm, Sweden), 43(2), 142-152.
[7] Al-Blesh, Mohammad Adnan Hashem.(2017). Identification and determination of Phenolic compounds in Brassica L. (Brassicaceae) species grow in Iraq,22(12) ,29-37.
[8] Janovska, D., K. Kubikova and L.kokoska. (2004).Screening for antimicrobial activity of some medicine plants .species of traditional chinese and medicine .Czech J.food Sci. 21( 3):107-110.
[9] Nair, A. B., & Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. Journal of basic and clinical pharmacy, 7(2), 27.
[10] Al- Shtayeh, M. S. A. and Abu Ghdeib, S. L. (1999). Antifungal activity of plant extract against dermatophytes. Mycoses, 42(1): 665-672.
[11] Guidet, B., & Shah, S. (1989). The level of malondialdehyde after activation with H2O2 and CuSO4 and inhibition by deferoxamine and molsidomine in the serum of patient with acute Myocardial infarction. National J. Chem, 5(1), 139-148.
[12] Al-Zamely, O. Y., Al-Nimer, M. S., & Al-Muslih, R. K. (2001). Detection the level of peroxynitrite and related antioxidant status in the serum of patients with acute myocardial infraction. Nation. J. Chem, 4(1), 625-637.
[13] Brown, M. S., & Goldstein, J. L. (1983). Lipoprotein metabolism in the macrophage: implications for foam cell formation. Annu Rev Biochem, 52(1), 223-261.
[14] Al-Qaisy, Rashid Khamis Shaban, (2016), Morphological and histopathological study of the effect of somedrugs used to reduce body weight and treated them by extract of leaves and seed oilof grapein kidnevs and liver of the pregnant female rats and their fetuses, Ph.D. thesis, College of Education for Pure Sciences, University of Tikrit. Tikrit. Iraq.120pp.
[15] Brown, N.J., & Vaughan, D.E. (1998). Angiotensin-converting enzyme inhibitors. Circulation, 97(14), 1411-1420.
[16] Srinivasan, K. K., Mathew, J. E., D’Silva, K. J. A., Lobo, R., & Kumar, N. (2015). Nephroprotective potential of Graptophyllum pictum against renal injury induced by gentamicin. Iranian Journal of Basic Medical Sciences, 18(4), 412.
[17] Schoolwerth, A. C., Sica, D. A., Ballermann, B. J., & Wilcox, C. S. (2001). Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation, 104(16), 1985-1991.
[18] Kok, R. J. (1998). Targeting of captopril to the kidney: towards selective renal ACE inhibition. University of Groningen. Amsterdam. S.N Publishing: 367pp.
[19] Sidorenkov, G., & Navis, G. (2014). Safety of ACE inhibitor therapies in patients with chronic kidney disease. Expert opinion on drug safety, 13(10), 1383-1395.